Please try another search
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Name | Age | Since | Title |
---|---|---|---|
John Michael Climaco | 52 | 2017 | Chairman of the Board, CEO & President |
Jerzy George Gumulka | 73 | 2017 | Independent Director |
Bettina M. Cockroft | 56 | 2023 | Independent Director |
Sigmund Hsu | - | - | Scientific Advisory Board Member |
Amy Mahery | - | 2024 | Independent Director |
Jeffry R. Keyes | 51 | 2018 | Independent Director |
Carl Anthony Evans | 76 | 2018 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review